This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cook, T. Articles by Sheridan, W. P. Search for Related Content PubMed PubMed Citation Articles by Cook, T. Articles by Sheridan, W. P.

Development of GnRH Antagonists for Prostate Cancer: New Approaches to Treatment

Amgen Inc., Thousand Oaks, California, USA

Correspondence: William P. Sheridan, M.D., Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA. Telephone: 805-447-3844; Fax: 805-498-1425; e-mail: sheridan{at}amgen.com

Prostate cancer has become the most common cancer among American men and is second only to lung cancer as a cause of male cancer-related death.

Several treatment options exist for different stages of prostate cancer including observation, prostatectomy, radiation therapy, chemotherapy, and hormone therapy. Hormone therapy has evolved from the use of estrogens to gonadotropin-releasing hormone (GnRH) agonists and recently, investigational GnRH antagonists.

GnRH receptor agonists such as leuprolide, bruserelin and goserelin have been used for the treatment of prostate cancer. These agonists eventually cause the inhibition of lutenizing hormone production, which in turn causes a suppression of testosterone and dihydrotestosterone, on which continued growth of prostate cancer cells depend.

Several comparative studies of leuprorelin administered as daily injections or monthly depot injections have been reported. Disease progression was prevented in more than 72% of men administered daily leuprorelin, and in 82% to 89% of those receiving monthly depots. Another synthetic GnRH analog, goserelin, has been studied in a similar population of men with daily injections producing partial responses in 60% to 80% of men with previously untreated prostate cancer. Abarelix, a peptide antagonist of GnRH receptor, is also being studied for the treatment of prostate cancer.

The discovery and development of GnRH antagonists may provide an important advance for patients with prostate cancer. Clearly the studies described herein, as well as many others, outline an exciting era of research to define the optimal use of hormonal therapy in prostate cancer.

Key Words. GnRH • Prostate cancer • Lutenizing hormone

This article has been cited by other articles:

				M. Princivalle, P. Broqua, R. White, J. Meyer, G. Mayer, L. Elliott, K. Bjarnason, R. Haigh, and C. Yea Rapid Suppression of Plasma Testosterone Levels and Tumor Growth in the Dunning Rat Model Treated with Degarelix, a New Gonadotropin-Releasing Hormone Antagonist J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 1113 - 1118. [Abstract] [Full Text] [PDF]

				K. Maiti, D. Y. Oh, J. S. Moon, S. Acharjee, J. H. Li, D. G. Bai, H.-S. Park, K. Lee, Y. C. Lee, N. C. Jung, et al. Differential Effects of Gonadotropin-Releasing Hormone (GnRH)-I and GnRH-II on Prostate Cancer Cell Signaling and Death J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4287 - 4298. [Abstract] [Full Text] [PDF]

				S. Palomba, F. Orio Jr., M. Morelli, T. Russo, M. Pellicano, C. Nappi, P. Mastrantonio, G. Lombardi, A. Colao, and F. Zullo Raloxifene Administration in Women Treated with Gonadotropin-Releasing Hormone Agonist for Uterine Leiomyomas: Effects on Bone Metabolism J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4476 - 4481. [Abstract] [Full Text] [PDF]

				P. Broqua, P. J.-M. Riviere, P. M. Conn, J. E. Rivier, M. L. Aubert, and J.-L. Junien Pharmacological Profile of a New, Potent, and Long-Acting Gonadotropin-Releasing Hormone Antagonist: Degarelix J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 95 - 102. [Abstract] [Full Text] [PDF]